Continuing our latest cell therapy mini-series, this time around we focus on a novel and creative approach to CAR-T cell therapy, which is quite different from what we have described before with other companies in this niche.
One emerging trend is the development of bi- and even tri- specific approaches designed to target multiple aberrations in the cancer cells, but what’s the best way to achieve this? Suppose we ditch the core dogma and try another way of doing things?
The entirely new concept making the splash is also coming from an emerging young biotech company few readers will likely have heard of, yet what they are doing reminds me we can borrow from the past and paraphrase a watch ad from the 1980’s for elegant and simple timepieces – some day all CAR-Ts will be made this way.
The secret sauce this time around isn’t quartz, however, but something completely different…
To learn more from our oncology analysis and get a heads up on insights and commentary on an emerging novel and creative CAR T cell therapy approach, subscribers can log-in or you can click to gain access to BSB Premium Content.
ASGCT Virtual: We are thoroughly enjoying the “live” annual meeting of the American Society of Gene and Cell Therapy (ASGCT).
Unlike other virtual meetings that have recorded presentations, ASGCT are running a live format, with presenters giving their talks in real-time from wherever in the world they may be. By and large this has worked well, and it definitely felt as though you were at the meeting.
We are also enjoying the ePoster hall, and in particular, the short audio tour that many presenters have made to take you through their poster. Obviously, it’s not a substitute for in-person contact, but who would want to be in a crowded poster hall or meeting room in these uncertain times with the potential for the coronavirus lurking about?
Earlier today we “attended” a virtual ASGCT20 scientific session with oral presentations organized by the American Society for Transplantation and Cellular Therapy (ASTCT) on Engineering Immunity.
Four speakers focused on CAR T cell therapy in non-B cell malignancies – what did we learn? It turns out the answer was quite a bit!
To find out more about our oncology analysis and get a heads up on insights and commentary emerging from the ASGCT meeting, subscribers can log-in or you can click to gain access to BSB Premium Content.
A high tide marker stands out on the beach, what stood out at ASGCT20 for you?
As Covid–19 continues to exert its impact on the cancer conference schedule, the good news is that it isn’t a total wrecking ball effect as organisations turn to virtual meetings to enable researchers to share their work.
Some of the events we have ‘attended’ this year have been prerecorded in advance, while others have taken the form of live events. Having listened to both, I can say they have advantages and disadvantages either way.
To me, it doesn’t really matter if you are flexible and appreciate the effort the scientists are making to show their wares.
This week it’s the turn of the American Society of Gene and Cell Therapy (ASGCT) to be in the spotlight with a truly ‘live’ meeting.
In the latest post, we focus on some key Gems from the Poster Halls…
To learn more from our oncology analysis and get a heads up on insights and commentary emerging from the ASGCT meeting, subscribers can log-in or you can click to gain access to BSB Premium Content.